Biondvax Pharmaceuticals Accounts Payable

Biondvax Pharmaceuticals (BVXV) currently reports a accounts payable of $650K as of June 2023. That compares with $2.1M in the prior-year period — down 68.4% year over year. Use the charts on this page to explore Biondvax Pharmaceuticals's accounts payable history and peer comparisons.

Biondvax Pharmaceuticals's accounts payable decreased from $2.1M to $650K — a 68.4% year-over-year decrease (period ending June 2023). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Biondvax Pharmaceuticals reported $650K in accounts payable as of June 2023. That compares with $2.1M in the prior-year period — down 68.4% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current accounts payable of $650K, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Biondvax Pharmaceuticals, and consider following BVXV for alerts when major investors trade the stock.

Biondvax Pharmaceuticals is classified in the Healthcare sector. On accounts payable, it currently shows $650K. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing BVXV with unrelated industries.